[email protected]   +1 (304) 306-0723

Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

$6,500.00$19,500.00

About 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist.  CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL)  in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.2 billion market by 2030.

Clear

Description

Acute Lymphoblastic Leukemia (ALL) is an aggressive form of Non-Hodgkin’s Lymphoma (NHL), most common among children under 5 years of age. Overall, about 4 of every 10 cases of ALL are in adults. The risk is slightly higher in males than in females, and higher in Caucasians. The risk of ALL increases after 50 years of age and is more likely to be fatal in adults than in children. Adult ALL has historically had a dismal prognosis, with limited treatment options and cure rates less than 40% due to higher-risk disease features and significant chemotherapy-associated toxicity.

Adult Acute Lymphoblastic Leukemia – Incidence (Epidemiology)

The total incident population of adult acute lymphoblastic leukemia (ALL) in the G7 markets is estimated to be 5173 in 2030 with a CAGR of 0.5%. The relapsed / refractory ALL population in G7 is expected to reach XXX by 2030 at a CAGR of 0.5%
Current treatment regimens result in 5-year event-free survival rates that exceed 85% in children (aged 1–21); however, disease relapse is associated with a poor outcome and ALL remains the leading cause of cancer-related death in children and young adults (aged 21–39). In general, about 80% to 90% of adults will have complete remissions at some point during these treatments which means leukemia cells can no longer be seen in their bone marrow. Unfortunately, about half of these patients’ relapse, so the overall cure rate is in the range of 40% whereas 10% to 20% of patients of the patients will refractory to leukemia. The relapse/refractory Adult Acute Lymphoblastic Leukemia (aALL) is found close to 50%.
Acute Lymphoblastic Leukemia Incidence
Traditionally, the four components of aALL treatment are induction, consolidation, maintenance, and central nervous system (CNS) prophylaxis. Most patients with aALL diagnosed, will receive hyper-CVAD regimen or standard chemotherapies for Ph negative ALL whereas tyrosine kinase inhibitors (TKIs) will be used in addition to the standard chemotherapies. Similar trends were found in all the country specific studies.
Marketed-Drugs-for-Acute-Lymphoblastic-Leukemia.

Adult Acute Lymphoblastic Leukemia – Current Market Size & Forecast Trends

The adult ALL therapy market size is expected to experience high growth throughout our study period, increasing from $XX billion in 2017 to $2.5 billion in 2030, representing 6.1 % annual growth. The opportunities to grow the market are evident, beginning from the epidemiology of the condition.
The primary drivers of market growth will be the continuous usage of the current treatments i.e., multi agent chemotherapies including Hyper-Cvad regimens and Tyrosine kinase inhibitors in the frontline adult ALL treatments. The relapsed/ refractory treatment market is driven by immunotherapies such as Blincyto/Blinatumomab (Amgen), Besponsa/ Inotuzumab ozogamicin (Bristol Meyers Squibb). We expect that with the uptake of the emerging treatments i.e., JZP-458 (Jazz Pharmaceuticals/Pfenex), Brexucabtagene autoleucel (Kite Pharma), Daratumumab (Janssen Biotech), AUTO 1 (Autolus) and PBCAR 0191 (Precision BioSciences) the market will increase double fold in the G7 countries. Despite new drug approvals, we also foresee slow growth in adult aALL current TKI therapy market growth due to small number of ALL patients.
Market-Forecast-Acute-Lymphoblatic-Leukemia

Report Highlights

  • Adult Acute Lymphoblastic Leukemia (aALL)– Current Market Trends
  • Adult Acute Lymphoblastic Leukemia (aALL)– Current & Forecasted Cases across the G7 Countries
  • Adult Acute Lymphoblastic Leukemia (aALL)– Market Opportunities And Sales Potential for Agents
  • Adult Acute Lymphoblastic Leukemia (aALL)– Patient-based Market Forecast to 2030
  • Adult Acute Lymphoblastic Leukemia (aALL)– Untapped Business Opportunities
  • Adult Acute Lymphoblastic Leukemia (aALL)– Product Positioning Vis-a-vis Competitors’ Products
  • Adult Acute Lymphoblastic Leukemia (aALL)– KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Acute Lymphoblastic Leukemia (ALL) Disease Background
    • Acute Lymphoblastic Leukemia (ALL) Definition
    • Causes & Risk Factors
    • Signs and Symptoms
    • Pathogenesis
    • Classification
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
    • United States
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • Germany
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • France
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • Italy
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • Spain
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • United Kingdom
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
    • Japan
      • Incident Cases of Adult Acute Lymphoblastic Leukemia (ALL)
      • Relapsed/ refractory Cases of Adult Acute Lymphoblastic Leukemia (ALL)
  • Current Unmet Needs in Acute Lymphoblastic Leukemia (ALL)
    • Unmet Needs
    • Key Barriers to CAR-T Therapy
    • Key Market Strategies for CAR-T Therapy
  • Current Treatment Paradigm
    • Treatment guidelines for adult Acute Lymphoblastic Leukemia (ALL)
    • Regulatory Approvals/Indication and Current Benchmarks
  • Current Treatment Chapters
    • Blinatumomab (Amgen)
    • Inotuzumab ozogamicin (Pfizer)
    • Dasatinib (Bristol-Myers Squibb)
    • Tisagenlecleucel (Novartis)
    • Ponatinib (Takeda)
    • Vincristine liposomal (Acrotech Biopharma)
    • Erwinaze (Jazz Pharmaceuticals)
    • Calaspargase pegol (Servier)
    • Asparaginase (Medac)
  • Emerging Therapies Chapters
    • Daratumumab (Janssen Biotech)
    • JZP-458 (Jazz Pharmaceuticals/Pfenex)
    • Brexucabtagene autoleucel (Kite Pharma/Gilead)
    • AUTO-1 (Autolus)
    • Cytarabine/daunorubicin (Jazz Pharmaceuticals)
    • PBCAR 0191 (Precision BioSciences)
    • Eryaspase (ERYtech Pharma)
    • Others
  • Cost Coverage and Reimbursement plan
    • United States Cost Coverage & Reimbursement for ALL Therapies
    • CAR-T Reimbursement Scenarios in the United States
    • Europe Cost Coverage & Reimbursement for ALL Therapies
    • CAR-T Reimbursement Scenarios in the Europe
    • CAR-T Reimbursement Scenarios in the Japan
    • Novartis CAR-T Therapy –Kymriah Launch Approach in the US and Europe
  • What’s New in 2020
  • Key Updates & Catalyst in ALL 2020-2021
  • Future Treatment Paradigm
    • Acute Lymphoblastic Leukemia (ALL)  Competitor Landscape and Approvals Anticipated
    • Future Treatment Algorithms and Competitor Positioning
    • Key Data Summary for Emerging Treatment
  • Total Market Forecast
    • Key Summary Findings
      • G7 total Market for Acute Lymphoblastic Leukemia (ALL) 2020-2030 (USD Million)
      • G7 total Market for Acute Lymphoblastic Leukemia (ALL)  by Therapies 2020-2030 (USD Million)
  • Market Forecast by Country
    • United States
      • United States Market for Acute Lymphoblastic Leukemia (ALL)  2020-2030 (USD Million)
      • United States Market for Acute Lymphoblastic Leukemia (ALL)  by Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Acute Lymphoblastic Leukemia (ALL)  2020-2030 (USD Million)
      • Germany Market for Acute Lymphoblastic Leukemia (ALL)  by Therapies 2020-2030 (USD Million)
    • France
      • France Market for Acute Lymphoblastic Leukemia (ALL)  2020-2030 (USD Million)
      • France Market for Acute Lymphoblastic Leukemia (ALL)  by Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Acute Lymphoblastic Leukemia (ALL) 2020-2030 (USD Million)
      • Italy Market for Acute Lymphoblastic Leukemia (ALL) by Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Acute Lymphoblastic Leukemia (ALL) 2020-2030 (USD Million)
      • Spain Market for Acute Lymphoblastic Leukemia (ALL) by Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Acute Lymphoblastic Leukemia (ALL) 2020-2030 (USD Million)
      • United Kingdom Market for Acute Lymphoblastic Leukemia (ALL) by Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Acute Lymphoblastic Leukemia (ALL) 2020-2030 (USD Million)
      • Japan Market for Acute Lymphoblastic Leukemia (ALL) by Therapies 2020-2030 (USD Million)
  • Market Drivers & Barriers
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going